Thus, the lack of cDC1s in tumors leads to insufficient priming, expansion, and tumor infiltration of tumor-specific T cells, which cumulatively compromise patient responsiveness to PD-1 blockade treatment. The gene discussed is PDCD1; the disease is neoplasm.